Inactive Instrument

News Spark Therapeutics Inc Nasdaq

Equities

End-of-day quote Nasdaq Other stock markets
-	-

May. 13	Senti Biosciences, Inc Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	CI
2023	Spark Therapeutics Terminates Collaboration Agreement for the Epilepsy Project CG01 with CombiGene AB	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Senti Biosciences, Inc Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	May. 13	CI
Spark Therapeutics Terminates Collaboration Agreement for the Epilepsy Project CG01 with CombiGene AB	23-10-14	CI
One of Nature’s journals publishes article about CombiGene’s epilepsy project	23-04-11	AQ
Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies Updates Cash Runway Guidance	23-01-30	AQ
Spark Therapeutics Enters Into Strategic Collaboration with Neurochase for Use of Proprietary Delivery Technology for CNS Disorders	23-01-30	AQ
Spark Therapeutics, Inc. Enters into Strategic Collaboration with Neurochase Limited for Use of Proprietary Delivery Technology for CNS Disorders	23-01-27	CI
Spark Therapeutics, Inc. Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A	22-12-12	CI
Watch CEO Jan Nilsson’s presentation at Aktiedagen Göteborg	22-05-17	AQ
CombiGene presents at Aktiedagen Göteborg on Monday 16 May	22-05-10	AQ
BioStock: CombiGene strives for a broader pipeline	22-04-21	AQ
Spark Therapeutics, Inc. Announces Executive Changes, Effective April 1, 2022	22-02-23	CI
CombiGene launches new website	22-02-21	AQ
Year-end report January-December 2021 CombiGene AB (Publ)	22-02-17	AQ
BioStock: CombiGene's CEO gives business development update	22-02-11	AQ
CombiGene’s and Neurochase’s preclinical study provides valuable information for the upcoming long-term studies in toxicology and biodistribution	22-02-08	AQ
GMP production of CG01 made available for preclinical studies planned to enable First in Human study	22-01-17	AQ
Spark Therapeutics to Invest $575M in New 500k Square Foot State-of-the-Art Gene Therapy Innovation Center on Drexel's University City Campus	21-12-20	AQ
BioStock: CombiGene's CEO about the path to the first clinical trial	21-12-20	AQ
CombiGene and Spark Therapeutics plan to expand the clinical development program to include the U.S. as well as Europe	21-12-16	AQ
Combigene and Spark Therapeutics Plan to Expand the Clinical Development Program to Include the U.S. as Well as Europe	21-12-16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Spark Therapeutics Inc Nasdaq

Equities

Summary

Filters